The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease

References

• Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-Chester disease. Eur J Intern Med [Internet]. 2015;26:223–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0953620515000771. doi:10.1016/j.ejim.2015.03.004.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis [Internet]. 2013;72:1691–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23396641. doi:10.1136/annrheumdis-2012-202542.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Berti A, Campochiaro C, Dagna L. Diagnosing Erdheim–Chester disease. Ann Rheum Dis [Internet]. 2013;72:e19 LP-e19. Available from: http://ard.bmj.com/content/72/7/e19.abstract
   Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, Deimling A Von, Hélias-rodzewicz Z, Hervier B, Cohen-aubart F, Launay D, Lesot A, Mokhtari K, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses Brief report High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700–3.
   PubMed Web of Science ®Google Scholar
• Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis [Internet]. 2015;74:1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24671772
   PubMed Web of Science ®Google Scholar
• Stoppacciaro A, Ferrarini M, Salmaggi C, Colarossi C, Praderio L, Tresoldi M, Beretta A A., Sabbadini MG. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: Implications for pathogenesis. Arthritis Rheum. 2006;54:4018–22. doi:10.1002/art.22280. PMID:17133532
   PubMed Web of Science ®Google Scholar
• Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, Ghillani-Dalbin P, Hervier B, Kahn JE, Deback C, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: A single-center series of 37 patients. Blood. 2011;117:2783–90. doi:10.1182/blood-2010-10-313510. PMID:21205927
   PubMed Web of Science ®Google Scholar
• Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: The paradigm of Erdheim-Chester disease. Front Immunol. 2014;5:1–6. doi:10.3389/fimmu.2014.00281. PMID:24474949
   PubMed Web of Science ®Google Scholar
• Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005;78:14–26. doi:10.1189/jlb.1204712. PMID:15784687
   PubMed Web of Science ®Google Scholar
• Islam S a, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J Exp Med [Internet]. 2013;210:1889–98. Available from: http://www.jem.org/cgi/doi/10.1084/jem.20130240\npapers3: //publication/doi/10.1084/jem.20130240 doi:10.1084/jem.20130240.
   PubMed Web of Science ®Google Scholar
• Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, Singh IS, Trojanowska M, Jimenez S a., White B. Pulmonary and Activation-Regulated Chemokine Stimulates Collagen Production in Lung Fibroblasts. Am J Respir Cell Mol Biol. 2003;29:743–9. doi:10.1165/rcmb.2003-0078OC. PMID:12805086
   PubMed Web of Science ®Google Scholar
• Prasse A, Pechkovsky D V., Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Müller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173:781–92. doi:10.1164/rccm.200509-1518OC. PMID:16415274
   PubMed Web of Science ®Google Scholar
• Prasse A, Pechkovsky D V., Toews GB, Schäfer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Müller-Quernheim J. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007;56:1685–93. doi:10.1002/art.22559. PMID:17469163
   PubMed Web of Science ®Google Scholar
• Boot RG, Verhoek M, Fost M De, Hollak CEM, Maas M, Bleijlevens B, Breemen MJ Van, Meurs M Van, Boven L a, Laman JD, et al. Marked elevation of the chemokine CCL18 / PARC in Gaucher disease : a novel surrogate marker for assessing therapeutic intervention. Blood 2004;103:33–9.
   PubMed Web of Science ®Google Scholar
• Hägg D a., Olson FJ, Kjelldahl J, Jernås M, Thelle DS, Carlsson LMS, Fagerberg B, Svensson PA. Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis. 2009;204:15–20. doi:10.1016/j.atherosclerosis.2008.10.010.
   Google Scholar
• Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007;9:1000–4. doi:10.1038/ncb434. PMID:17762890
   PubMed Web of Science ®Google Scholar
• Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G. TGF-β and fibrosis in different organs – molecular pathway imprints. Biochim Biophys Acta – Mol Basis Dis. 2009;1792:746–56. doi:10.1016/j.bbadis.2009.06.004.
   PubMed Web of Science ®Google Scholar
• Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13:616–30. doi:10.1038/nrm3434. PMID:22992590
   PubMed Web of Science ®Google Scholar
• Cavalli G, Justice JN, Boyle KE, D'Alessandro A, Eisenmesser EZ, Herrera JJ, Hansen KC, Nemkov T, Stienstra R, Garlanda C, et al. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci [Internet]. 2017;114:2313–8. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1619011114. doi:10.1073/pnas.1619011114.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev [Internet]. 2018;281:179–90. Available from: doi.wiley.com/10.1111/imr.12605. doi:10.1111/imr.12605.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Koenders M, Kalabokis V, Kim J, Tan A, Garlanda C, Mantovani A, Dagna L, Joosten LA, Dinarello CA, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016;55:2220–9. doi:10.1093/rheumatology/kew325. PMID:27567100
   PubMed Web of Science ®Google Scholar
• Cives M, Simone V, Rizzo FM, Dicuonzo F, Cristallo Lacalamita M, Ingravallo G, Silvestris F, Dammacco F. Erdheim–Chester disease: A systematic review. Crit Rev Oncol Hematol [Internet]. 2015; Available from: http://linkinghub.elsevier.com/retrieve/pii/S1040842815000281. doi:10.1016/j.critrevonc.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Néel A, Hamidou M a., Kahn JE, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients. Blood. 2011;117:2778–82. doi:10.1182/blood-2010-06-294108. PMID:21239701
   PubMed Web of Science ®Google Scholar
• Ferrero E, Corti A, Haroche J, Belloni D, Colombo B, Berti A, Cavalli G, Campochiaro C, Villa A, C-AF, Amoura Z, et al. Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. Oncoimmunology. 2016;5:e1181244. doi:10.1080/2162402X.2016.1181244. PMID:27622037
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G DL. Advances in potential targeted therapies for Erdheim-Chester disease. Expert Opin Orphan Drugs. 2017;5:253–60.
   Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–32. doi:10.1182/blood-2010-07-273417. PMID:21304099
   PubMed Web of Science ®Google Scholar
• Cavalli G, Hayashi M, Jin Y, Yorgov D, Santorico SA, Holcomb C, Rastrou M, Erlich H, Tengesdal IW DL, et al. MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A. 2016;113:1363–8. doi:10.1073/pnas.1523482113. PMID:26787888
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Baldissera E DL. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol. 2015;44:309–14. doi:10.3109/03009742.2014.992949. PMID:25656459
   PubMed Web of Science ®Google Scholar
• Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M DL. Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. Front Immunol. 2017;8:131. doi:10.3389/fimmu.2017.00131. PMID:28232838
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Cantarini L CE, Cavallaro E, et al. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017;8:369. doi:10.3389/fphar.2017.00369. PMID:28659802
   PubMed Web of Science ®Google Scholar
• Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L TM. Treating Life-Threatening Myocarditis by Blocking Interleukin-1. Crit Care Med. 2016;44:e751–4. doi:10.1097/CCM.0000000000001654. PMID:27031379
   PubMed Web of Science ®Google Scholar
• Cavalli G DC. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatol. 2015;54:2134–44.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Fallanca F, Dinarello CA DL. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015;191:596–8. doi:10.1164/rccm.201412-2150LE. PMID:25723826
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, Silva NM, Renand A, Galateau-Salle F, Le Toquin S, Bensadoun H, Larousserie F, Silvera S, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood [Internet]. 2010;116:4070–6. Available from: https://doi.org/10.1182/blood-2010-04-279240. doi:10.1182/blood-2010-04-279240.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124:483–92. doi:10.1182/blood-2014-03-561381. PMID:24850756
   PubMed Web of Science ®Google Scholar